| ¿µ¹® | enzyme-linked immunoabsorbent assay | ÇÑ±Û | È¿¼Ò¸é¿ªÃøÁ¤¹ý |
|---|---|---|---|
| ¼³¸í | È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸ÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë ŰƮµµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù. |
||
| CPBA | Competitive Protein Binding Assay |
|---|---|
| CBPA | competitive protein-binding assay |
| LAI assay | Leukocyte Adherence Inhibition assay |
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| IFA | idiopathic fibrosing alveolitis; immunofluorescence assay; immunofluorescent antibody; incomplete Fr... |
| C-ELISA | Competitive enzyme-linked immunosorbent assay |
|---|---|
| C-ELISA | Competitive ELISA |
| cPCR | Competitive PCR |
| CE | Competitive exclusion |
| cPCR | Competitive polymerase chain reaction |
| competitive binding assay | General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards. See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay. Synonym: displacement analysis, saturation analysis. (05 Mar 2000) |
|---|---|
| competitive antagonist | An antimetabolite. (05 Mar 2000) |
| competitive behaviour | The direct struggle between individuals for environmental necessities or for a common goal. (12 Dec 1998) |
| competitive bidding | Pricing statements presented by more than one party for the purpose of securing a contract. (12 Dec 1998) |
| competitive inhibition | <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding. at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same. (05 Jan 1998) |
| competitive medical plans | Alternative health care delivery mechanisms, such as preferred provider organizations or other health insurance services or prepaid plans (other than health maintenance organizations), that meet medicare qualifications for a risk-sharing contract. (12 Dec 1998) |
| acetyl reduction assay | <investigation> A technique for measuring the nitrogen fixation activity in photosynthetic organisms. It uses a flame ionisation detector and a gas chromatography apparatus to determine the reduction of acetylene to ethylene by the enzyme nitrogenase. (06 May 1997) |
| Ames assay | <procedure> One of a number of procedures used to test substances for likely ability to cause cancer that combines the use of animal tissue to generate active metabolites of the substance with a test for mutagenicity in bacteria. (18 Nov 1997) |
| antibiotic assay | <investigation> A test to determine how sensitive a bacterial or fungal strain is to arange of antibiotics bymeasuring the microbes' ability to grow in astandard dilution of each chemical. (09 Oct 1997) |
| assay | <procedure> The determination of the amount of a particular constituent of a mixture or of the biological or pharmacological potency of a drug. (10 May 1997) |
| bandshift assay | <investigation> An assay for proteins, such as transcription factors, that bind specific DNA sequences. A labelled oligonucleotide corresponding to the recognition sequence is incubated with an appropriate nuclear protein extract and run on a nondenaturing acrylamide gel. Oligonucleotides that have been bound by proteins are retarded relative to those that are unbound. (18 Nov 1997) |
| biological assay | <technique> Once a pharmaceutical protein is isolated from the cells in which it was grown, researchers perform tests to measure the protein's biological activity. It must maintain a certain minimal level of biological activity to be used for animal or clinical testing or, later, for market. Researchers also test to confirm that the isolated protein is identical to the desired protein. (21 Mar 1998) |
| radioimmunoprecipitation assay | Sensitive assay using radiolabelled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as protein a sepharose beads. The bound radiolabelled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (ripa) is often used as a confirmatory test for diagnosing the presence of HIV antibodies. (12 Dec 1998) |
| radioligand assay | <radiobiology> Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labelled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). (12 Dec 1998) |
| radioreceptor assay | A competitive binding assay in which the binder is a membrane or tissue receptor rather than an antibody. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|